IDE 161
Alternative Names: IDE-161Latest Information Update: 01 Jul 2025
At a glance
- Originator IDEAYA Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly ADP ribose glycohydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from the preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research 2025 (AACR-2025)
- 04 Nov 2024 IDEAYA Biosciences plans a phase I trial for Endometrial cancer(Combination therapy) in the fourth quarter of 2024.
- 23 Oct 2024 Pharmacodynamics data from the preclinical studies in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)